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Pharmacological reactivation of human immunodeﬁciency virus (HIV) expression from
latent proviruses coupled with fully suppressive antiretroviral therapy (ART) has been
suggested as a strategy to eradicate HIV infection. In order for this strategy to be effective,
latently infected cells must be killed either by the cytopathic effect of reactivated HIV gene
expression, or by HIV-speciﬁc cytotoxic T lymphocyte (CTL). However, a review of current
data reveals little evidence that CTL retain an antiviral effector capacity in patients on fully
suppressive ART, implying that the HIV-speciﬁc CTL present in these patients will not be
able to eliminate HIV-infected CD4+T cells effectively. If this is due to functional impairment
or a quantitative deﬁcit of HIV-speciﬁc CTL during ART, then therapeutic vaccination may
improve the prospects for eradicating latent reservoirs. However, data from the macaque
simian immunodeﬁciency virus (SIV) model indicate that in vivo, SIV-speciﬁc CTL are only
effective during the early stages of the viral replication cycle, and this constitutes an
alternative explanation why HIV-speciﬁc CTL do not appear to have an impact on HIV
reservoirs during ART. In that case, immunotoxins that target HIV-expressing cells may
be a more promising approach for HIV eradication.
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INTRODUCTION – ANTIRETROVIRAL THERAPY, ERADICATION
STRATEGIES, AND THE POSSIBLE ROLE OF HIV-SPECIFIC CTL
Current regimens of antiretroviral therapy (ART) are able to sup-
press human immunodeﬁciency virus (HIV) replication to levels
that are practically undetectable, and many observations indi-
cate that complete inhibition of active HIV replication is indeed
attained in patients on prolonged ART (McMahon et al., 2010;
Yukl et al., 2010; Hatano et al., 2011; Besson et al., 2012; Gandhi
et al., 2012).
Unfortunately, the integration of replication-competent HIV
proviral genomes into host cell DNA creates a viral reservoir that
is unaffected by ART (Chun et al., 1997, 2005; Finzi et al., 1997;
Viard et al., 2004). These proviruses can be reactivated when the
host T cell is stimulated by antigen or by cytokines (Chun et al.,
1998; Wang et al., 2005), and as this inevitably occurs in a normal
environment,HIV replication continually reignites from the smol-
dering ember of proviral DNA, leading to rebound viremia and a
resumption of disease progressionwhenART is discontinued. This
implies that eradication of the proviral reservoir will be a neces-
sary part of therapeutic strategies aiming to cure HIV infection
(Trono et al., 2010; Deeks et al., 2012). To this end, several groups
have demonstrated that histone deacetylase (HDAC) inhibitors
(Lehrman et al., 2005; Contreras et al., 2009), protein kinase C
agonists (Kulkosky et al., 2001; Korin et al., 2002), and cytokines
that activate the Janus kinase/signal transducers and activators
of transcription (JAK/STAT) signaling pathway (Scripture-Adams
et al., 2002; Wang et al., 2005) can reactivate HIV expression from
latent proviral genomes. The activity of one HDAC inhibitor,
Vorinostat (also known as suberoylanilide hydroxamic acid,
or SAHA), has been demonstrated in patients (Archin et al.,
2012), strongly indicating that this may be a clinically viable
approach.
However, this strategy for the eradication of HIV hinges on the
assumption that latently infected cells will be killed by the reacti-
vation of latent proviruses, either as a result of cytopathic effects
of HIV gene expression, or through lysis by HIV-speciﬁc cytotoxic
T lymphocyte (CTL). In a recent landmark study, Siliciano and
colleagues found that reactivation of HIV provirus by Vorinos-
tat was not cytopathic, and that elimination of latently infected
cells required their recognition and lysis by functionally compe-
tent HIV-speciﬁc CTL (Shan et al., 2012). The success of clinical
trials aiming to eradicate latent reservoirs of HIV infection may
therefore depend on the presence of functional HIV-speciﬁc CTL
in patients who have experienced several years of ART.
Four distinct lines of evidence indicate that CTL limit HIV
replication in both the acute and chronic phase of untreated HIV
infection. These are: (1) associations between human leukocyte
antigen (HLA) class I alleles and disease progression; (2) HIV
sequence evolution and polymorphism indicating selection pres-
sure exerted by CTL in vivo; (3) inverse correlation of viral load
(VL) with Gag-speciﬁc CTL responses; and (4) ability of CTL to
inhibit HIV replication ex vivo.
For each of these types of evidence, I will brieﬂy summarize
what the approach has revealed about the CTL response dur-
ing untreated HIV infection, then review the relevant data in
patients on ART, in order to assess to what extent HIV-speciﬁc
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CTL continue to have an antiviral function during ART. In the
light of this data, two alternative strategies aiming to eradicate
infected cells with reactivated latent infection will be discussed.
ASSOCIATIONS BETWEEN HLA CLASS I ALLELES AND
DISEASE PROGRESSION
In untreated HIV infection, associations between HLA genetic
polymorphism and disease progression were identiﬁed in sev-
eral studies, using both candidate gene (reviewed in Carrington
and O’Brien, 2003), and genome-wide strategies (The Interna-
tional HIV Controllers Study, 2010). The observation that HLA
class I genotype has a strong inﬂuence on the progression of
HIV infection suggested that CTL play an important role in the
natural history of the disease. The HLA-B polymorphisms asso-
ciated with disease progression inﬂuence the peptide repertoire
presented by the allele, indicating that favorable HLA-B alleles,
such as B27, B57, and thewider Bw4 allele group, confer protection
toHIVdisease because they present the“best”HIVepitopes toCTL
– that is, those epitopes in which escape mutations incur a high
ﬁtness cost to the virus (Carrington and Walker, 2012; Goulder
and Walker, 2012).
Although ART effectively halts clinical disease progression
in the majority of patients, its success rate is not 100%, and
a signiﬁcant proportion of patients on ART experience either
immunological failure, deﬁned as poor or no recovery of CD4+ T
lymphocyte count, or virological failure, characterized by the per-
sistence of plasma virus. If CTL lysis of infected cells contributes
to the efﬁcacy of treatment, then one should expect genetic asso-
ciations between HLA class I alleles and treatment outcome. Four
published studies have tested this hypothesis (Brumme et al., 2007;
Ahuja et al., 2008; Rauch et al., 2008; Kuniholm et al., 2011), and
the results are summarized in Table 1. Overall, none of the HLA
alleles associated with protective effects in untreated HIV infec-
tion are associated with positive treatment outcomes in patients
on ART. Indeed, the associations that have been most consistently
reported are between the presence of “protective” HLA-B alleles
and higher risk of immunological failure in patients on ART. In
contrast, the cysteine–cysteine chemokine receptor 5 (CCR5Δ32)
polymorphism was associated with better virological response to
ART (Brumme et al., 2005; Laurichesse et al., 2007).
The physiological interpretation of these results is far from
clear. It is intriguing that in two studies (Ahuja et al., 2008; Kuni-
holm et al., 2011), the same alleles that are associated with better
control of viral replication andmaintenance of CD4+ T cell counts
in untreated HIV infection were associated with poorer CD4+ T
cell recovery during therapy. One scenario that could explain these
observations is that HIV-speciﬁc CTL continue to lyse cells pre-
senting their cognate HLA–peptide complex during ART, but that
this is detrimental, rather than beneﬁcial, for CD4+ T cell recovery,
so that the more efﬁcient the anti-HIV CTL response, the more
CD4+ T cell recovery is impaired.
HIV SEQUENCE EVOLUTION INDICATING SELECTION
PRESSURE FROM CTL
Studies of HIV sequence evolution over time (Borrow et al., 1997;
Goulder et al., 1997; Cao et al., 2003; Allen et al., 2005), and associ-
ations between HIV sequence polymorphisms and the HLA type
of the infected person (Moore et al., 2002; Brumme et al., 2009),
have shown that escape from CTL responses occurs during HIV
infection by the selection of mutations in and around CTL epi-
topes. These mutations either abrogate peptide binding to the
presenting HLA, inﬂuence processing of the epitope, or prevent
binding of the HLA–peptide complex to its cognate T cell receptor
(TCR; Goulder and Watkins, 2004), and their emergence indi-
cates that CTL exert selection pressure on the viral quasispecies in
vivo. MultipleHLA-A andHLA-B alleles are associatedwith escape
mutations (Moore et al., 2002; Brumme et al., 2009), showing that
CTL restricted by non-protective HLA alleles do in fact have an
impact on HIV replication in infected patients. Fitness constraints
limit the number of possible escape variants that are available to
the virus, and the protective alleles HLA-B27, 5701, and 5801 tar-
get epitopes with few viable escape variants (Brockman et al., 2007;
Miura et al., 2009), which to a large extent explains the associations
of these alleles with slower disease progression.
Two studies found statistical associations between patient’s
HLA, and mutations that accumulated in either the protease or the
reverse transcriptase (RT) proteins during virological failure (John
et al., 2005; Mueller et al., 2007), indicating that the CTL response
inﬂuences the emergence of drug resistance mutations. More
recently, a powerful longitudinal analysis of virus sequences from
Table 1 | Reported associations between HLA alleles and immunological and virological response to ART.
Cohort size Immunological response Virological response Reference
765 Slower CD4+ recovery in patients homozygous at
any HLA class I locus
No association Brumme et al. (2007)
502 Slower CD4+ recovery in patients carrying
HLA-B57
Not tested Ahuja et al. (2008)
265 Slower CD4+ recovery in patients homozygous for
the Bw4 allele group
No association Rauch et al. (2008)
860 Slower CD4+ recovery in patients homozygous for
the Bw4 allele group
Tendency toward poorer immunological response
in patients carrying B5701 and B5801
Patients carrying B5701 and B5801 less likely to attain VL
< 500 copies/mL within 12 months of treatment initiation
Kuniholm et al. (2011)
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619patients, sampled before andduringARTwas reported (Knapp
et al., 2012). HIV protease and RT sequences were obtained from
plasma samples with VL > 1000 copies/mL, and a median of ﬁve
post-ART samples were sequenced per patient. The availability of
pre-treatment sequences made it possible to determine unequiv-
ocally whether CTL escape mutations had been selected before or
during ART. Overall, 43% of patients developed at least one addi-
tional CTL escape mutation over the period on ART (median 5.1
years), and the mean rate of accumulation of CTL escape muta-
tions was estimated to be sevenfold slower during ART, compared
to before treatment initiation.
In the context of successful ART, the low levels of plasma VL
pose a technical challenge for longitudinal analysis of HIV RNA
sequences. Two published studies did however succeed in just such
an undertaking, using ultracentrifugation to concentrate virus
particles from plasma before RNA extraction. Casazza et al. (2005)
studied the sequences of six CTL epitopes in three patients with
VL< 400 copies/mL, and found evidence of sequence evolution in
CTL epitopes during ART in one of three patients studied. Simi-
larly, in amore recent study of 20 patients withVL< 50 copies/mL,
sequences were obtained for 12 study participants, and evidence
for selection of CTL escape mutations was found in three patients
(Shiu et al., 2009).
These ﬁve studies all found evidence of accumulation of CTL
escape mutations during ART, with the rate of accumulation cor-
related with the level of ongoing viral replication in two studies
(Shiu et al., 2009; Knapp et al., 2012). This observation may indi-
cate that at lower VLs, CTL responses exert less pressure on the
virus, due to the reduced number of circulating HIV-speciﬁc CTL
(see below). On the other hand, as virus replication is suppressed,
fewer mutations arise, and escape mutations accumulate more
slowly. As an extreme example, in patients with complete suppres-
sion of viral replication, no escape mutations can arise because the
virus no longer has the means to respond to any type of selection
pressure – but that does not imply that the selection pressure has
ceased to exist.
The pressure that CTL exert on HIV therefore appears to be
maintained during ART and can be detected in some patients
even when VL is reduced to<50 copies/mL. However, the relative
potency of this selection pressure (as strong as, or weaker than that
observed during primary or chronic infection) cannot be inferred
from these studies.
ASSOCIATIONS BETWEEN PRESENCE OF CTL AND
PLASMA VL
Cytotoxic T lymphocyte can exert selection pressure on the virus
only if they are in fact present in the infected person, and evidence
for the antiviral effect of CTL in untreated HIV infection was
also provided by documenting associations between the presence
of HIV-speciﬁc CTL and lower VL. During acute infection, the
appearance of HIV-speciﬁc CTL coincides with the reduction of
VL from its peak to its set-point value (Borrow et al., 1994; Koup
et al., 1994), and in chronic infection, cross-sectional studies in
many different cohorts showed that the number of Gag-speciﬁc
CTL is inversely correlated with VL (Klein et al., 1995; Ogg et al.,
1998; Buseyne et al., 2002; Edwards et al., 2002; Zuñiga et al., 2006;
Kiepiela et al., 2007).
Following the initiation of ART, the numbers of circulating
HIV-speciﬁc CTL decline with two-stage kinetics (Ogg et al., 1999;
Casazza et al., 2001), so that thenumber of circulatingHIV-speciﬁc
CTL is reduced 5- to 10-fold over the ﬁrst 1–2 years of ART. This
indicates that antigenic stimulation maintains the levels of CTL
observed in untreated patients, so that when virus replication is
suppressed by ART, CTL responses wane. However, HIV-speciﬁc
CD8+ T lymphocytes do not entirely disappear in patients on
ART, and HIV-speciﬁc CTL can be detected in many patients after
several years of effective ART (Appay et al., 2002; Oxenius et al.,
2002; Rehr et al., 2008). Two studies have addressed whether these
“residual”HIV-speciﬁc CTL responses might be related to residual
virus replication during suppressive ART. Both found that resid-
ual viral replication during ART, measured either by the amount
of intracellular HIV RNA (Patterson et al., 2001), or the occur-
rence of transient low-level (50–1000 copies/mL) viremic blips
(Papasavvas et al., 2006), was not related to the presence of CD8+
T cell responses.
In the context of partially effective ART, the available data
are somewhat equivocal. One study found that in patients with
low VL on ART (200 < VL < 10,000 copies/mL), or virologi-
cal failure (VL > 10,000 copies/mL), Gag-speciﬁc CD8+ T cells
were inversely correlated with VL (Alatrakchi et al., 2005), and
overall, Gag-speciﬁc CD8+ responses were stronger in patients
with partial control of viral replication compared to those with
full virological failure. Similar results were found in a study of
pediatric patients (Buseyne et al., 2005), whereas a third study
found that the Gag-speciﬁc interferon-gamma (IFN-γ) response
in CD8+ T cells was not different in partial controllers (VL 500–
6000 copies/mL) compared to patients with uncontrolled HIV
replication (>10,000 copies/mL; Emu et al., 2005). In all three
studies, however, Gag-speciﬁc CD8+ T cells responses were lower
in patients with VL < 200 copies/mL, indicating that a certain
threshold of persistent HIV replication is required to reactivate
HIV-speciﬁc CTL during ART (Jin et al., 2000).
Although the number of studies addressing this issue is small,
none of them found an association between the presence of HIV-
speciﬁc CTL, and the absence of residual viral replication during
suppressive ART. This implies that any effect of HIV-speciﬁc CTL
on residual viremia during ART must be minor compared to viro-
logical factors such as pre-therapy VL (Palmer et al., 2008), and
the duration and composition of ART (Bonora et al., 2009).
EFFECTOR FUNCTION OF HIV-SPECIFIC CTL DURING ART
Finally, quality as well as quantity appears to inﬂuence the impact
of HIV-speciﬁc CTL on the virus. This concept was highlighted
by studies of HIV controllers, who maintain VL at a level of
<500 copies/mL in the absence of ART (Grabar et al., 2009).
HIV-speciﬁc CTL from controllers have a higher proportion of
multi-functional effector cells, capable of secreting tumor necro-
sis factor-alpha (TNF-α) and interleukin-2 (IL-2) in addition
to IFN-γ and macrophage inﬂammatory protein 1 beta (MIP-
1β), and show greater proliferation after stimulation with antigen
(Betts et al., 2006; Migueles et al., 2008; Pereyra et al., 2008;
Almeida et al., 2009) compared to HIV-speciﬁc CTL from patients
with chronic progressive infection. In addition, CD8+ T lym-
phocytes from most HIV controllers show rapid de novo perforin
www.frontiersin.org March 2013 | Volume 4 | Article 52 | 3
“ﬁmmu-04-00052” — 2013/2/28 — 10:25 — page 4 — #4
McIlroy HIV-speciﬁc CTL during ART
FIGURE 1 | Antiviral activity of HIV-specific CTL during early and late
phases of virus replication. (A) During the pre-integration stages of HIV
replication, virus-speciﬁc CD8+ T lymphocytes can inhibit viral replication
through the release of soluble mediators, such as MIP-1α, which blocks virus
entry, and/or by lysing infected cells presenting peptides derived from
incoming capsid antigens. During the post-integration stages, virus-speciﬁc
CD8+ T lymphocytes lyse cells expressing viral genes from integrated
provirus, thus reducing the number of progeny virions that are released per
infected cell. (B) Model 1: HIV-speciﬁc CTL are functionally impaired, and/or
present in insufﬁcient numbers during ART, so HIV-infected cells cannot be
eliminated effectively. This deﬁciency may be corrected by therapeutic
vaccination. (C) Model 2: HIV-speciﬁc CTL only have an impact in vivo during
the early stages of virus replication, so have no effect on the release of virus
from reactivated latent provirus. Even if CTL remain functionally competent or
are boosted through therapeutic vaccination during ART, they have no impact
on viral reservoirs.
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expression (Hersperger et al., 2010), and can suppress HIV repli-
cation in an ex vivo assay (Sáez-Cirión et al., 2009). Control of
HIV replication in this assay was dependent on cell–cell contact,
and did not involve soluble inhibitors of HIV replication (Sáez-
Cirión et al., 2007), suggesting that highly efﬁcient lysis of infected
target cells is what enables CD8+ T cells from HIV controllers to
suppress HIV replication in vivo (Figure 1A).
If the ability to suppress virus replication in an ex vivo assay is a
valid measure of in vivo antiviral efﬁcacy, to what extent do HIV-
speciﬁc CTL recover this capacity during ART? Two longitudinal
studies found that the functional “exhaustion” of HIV-speciﬁc
CTL (Day et al., 2006; Trautmann et al., 2006; Jones et al., 2008)
observed in viremic patients is reversed during ART (Rehr et al.,
2008; Streeck et al., 2008). However, several studies found that
the functional capacities of HIV-speciﬁc CTL from patients on
fully suppressive ART remain inferior to those observed in HIV
controllers. In particular, HIV-speciﬁc CTL from controllers
maintained a greater proliferative capacity, and displayed more
efﬁcient suppression of HIV replication than CTL from patients
on ART (Migueles et al., 2008, 2009; Sáez-Cirión et al., 2009; Shan
et al., 2012).
Antiretroviral therapy therefore appears to restore many effec-
tor functions in HIV-speciﬁc CTL, but at the same time, the
number of circulating HIV-speciﬁc cells decreases, and their abil-
ity to lyse infected cells remains inferior to that seen in HIV
controllers.
CONCLUSION
During partially effective ART, in patients with active HIV replica-
tion and VL > 1000 copies/mL, the accumulation of CTL escape
mutations in virus sequences, and the inverse correlation between
Gag-speciﬁcCTL andVLboth indicate thatHIV-speciﬁcCTL con-
tinue to have an impact on HIV replication. CTL may therefore
play a role in limiting the replication of drug-resistant virus during
virological failure of ART. In contrast, there is little evidence that
CTL continue to exercise an antiviral effector function in patients
on fully suppressive ART.
With respect to HIV eradication strategies based on pharmaco-
logical reactivation of latent proviruses, the available data suggests
that the HIV-speciﬁc CTL present in patients on fully suppres-
sive ART will not be able to eliminate HIV-infected CD4+ T cells
effectively. If this is entirely due to a degree of functional impair-
ment and a quantitative deﬁcit in CTL during ART (Figure 1B),
then restimulating HIV-speciﬁc CTL by therapeutic vaccination
may improve the prospects for eradicating latent reservoirs. How-
ever, observations in the macaque simian immunodeﬁciency virus
(SIV) model suggest an alternative explanation why HIV-speciﬁc
CTL do not have an antiviral effector function during ART. By
depleting CD8+ T cells in SIV-infected animals prior to the ini-
tiation of ART, then analyzing the kinetics of VL reduction, two
groups showed that both the virological response to ART, and
the in vivo half-life of productively infected cells were indepen-
dent of the presence of SIV-speciﬁc CTL (Klatt et al., 2010; Wong
et al., 2010). These results indicate that in vivo, SIV-speciﬁc CTL
only have an impact on the early stages of the viral replication
cycle (Figure 1C), either through release of soluble inhibitors
of HIV replication (such as the CCR5 ligand, MIP-1α), or by
lysis of infected cells before the expression of viral genes, due to
the presentation of peptides from incoming virus capsids (Sacha
et al., 2007; Payne et al., 2010). If a similar situation pertains
in HIV infection, then therapeutic vaccination will not have an
impact on HIV reservoirs – even in conjunction with interven-
tions that reactivate latent provirus – because infected cells with a
reactivated provirus only go through the later stages of a HIV
replication cycle. In this case, immunotoxins that target Env
on the surface of HIV-infected cells (Brooks et al., 2003; Berger
and Pastan, 2010) may be a more promising approach for HIV
eradication.
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